A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Abroad (travel likely)RecruitingPHASE3

Conditions

Neuromyelitis Optica Spectrum Disorder · NMOSD

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Children's Hospital Colorado., Denver, Colorado, United States

  • Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan, Ciudad Autonoma Buenos Aires, Argentina

  • Clinica Universitaria Reina Fabiola, Córdoba, Argentina

  • Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China

  • Children's Hospital of Fudan University, Shanghai, Shanghai Municipality, China

  • Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France

  • IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN, Rome, Lazio, Italy

  • Fondazione Istituto Neurologico Mondino IRCCS, Pavia, Lombardy, Italy

  • Grupo Medico Camino, DF, Mexico CITY (federal District), Mexico

  • Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

  • Instytut "Pomnik - Centrum Zdrowia Dziecka", Warsaw, Poland

  • Kocaeli University Research and Application Hospit, Kocaeli, Turkey (Türkiye)

  • Great Ormond Street Hospital for Children, London, United Kingdom

Study leads
  • Clinical Trials

    Study Director

    Hoffmann-La Roche